Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 13/20 | 0.60 |
| ▸ | CES1 | P23141 | 12/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzil SCHEMBL8189065 | 0.85 | CES2 (0.70) | CES2CES1RAB9AMAPTL3MBTL1 | |
| SCHEMBL14947050 | 0.83 | CES2 (0.65) | CES2CES1RAB9ATNFKLF5 | |
| Water SCHEMBL8945938 | 0.82 | CES2 (0.62) | CES2CES1RAB9ATNFKLF5 | |
| SCHEMBL65824 | 0.81 | SRD5A2 (0.61) | KMT2ATDP1ALDH1A1 | |
| Bicarbonate SCHEMBL8995866 | 0.81 | MAPT (0.58) | MAPTKMT2AALDH1A1 | |
| SCHEMBL16034288 | 0.80 | KMT2A (0.50) | RAB9ATNFKLF5NOD1MAPT | |
| SCHEMBL2834217 | 0.79 | CES2 (0.83) | CES2CES1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL1244791 | 0.79 | SRD5A2 (0.59) | KMT2ATDP1ALDH1A1 | |
| Acetic Acid SCHEMBL3621605 | 0.79 | MAPT (0.56) | MAPTKMT2AALDH1A1 | |
| Benzil SCHEMBL27757984 | 0.78 | CES2 (0.82) | CES2CES1RAB9AMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379251-B1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20060142178-A1 | Method of treating cancer | BARNETT STANLEY F | 2006-06-29 | — | — | US | disclosed |
| US-7034026-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1379251-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1496981-A2 | METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040143117-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2004-07-22 | — | — | US | disclosed |
| US-20040106540-A1 | Method of treating cancer | BARNETT STANLEY F (US) | 2004-06-03 | — | — | US | disclosed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1379251-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1379250-A2 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003084473-A2 | METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2002083064-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083138-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143117-A1 | Inhibitors of akt activity | AKT1, AKT2, AKT3 | CES2 3583/4885CES1 3145/4885RAB9A 1605/4885 |
| US-20040102360-A1 | Combination therapy | MTOR, AKT2, PLK1 | CES2 2798/4885CES1 3440/4885RAB9A 2008/4885 |
| US-20060142178-A1 | Method of treating cancer | PACSIN2, CTTN, TNK2 | CES2 3304/4885CES1 2954/4885RAB9A 2460/4885 |
| US-20040106540-A1 | Method of treating cancer | PACSIN2, CTTN, PLK1 | CES2 3149/4885CES1 2845/4885RAB9A 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.